Business News & Financial News

The Canadian group called Potash Monday its shareholders to reject hostile takeover bid from mining giant BHP Billiton and said he was discussing with other possible suitors for an alternative giving it a better value.

The world's largest producer of potash added in a statement expected to bring proposals have higher than 39 billion dollars (30.7 billion euros) made by BHP or other strategic options.

Discussions were held with several parties in order to generate higher offers, he said.

According to Bloomberg, Potash has been contacted by the Chinese and Brazilian Vale Sinochem.

The action Potash gained 1% in pre-market transactions on the New York Stock Exchange, to $ 151.

The action BHP gained about 2% in London, to 1858.5 pence.

In attempting to seize the biotech Genzyme, Sanofi-Aventis hopes to enter a segment long ignored by major pharmaceutical companies, one of rare diseases.

It would appear that the giants of the industry think that investing in this field can be a good way to increase margins, complete the range of products and at least partially offset the impact of competition from generic.

Pfizer and GlaxoSmithKline have already tried the adventure but the offer from Sanofi on Genzyme – which could turn around 14.3 billion euros – would be by far the most advanced.

Genzyme is the world leader in treatments for rare diseases.He realized in 2009 a turnover of around 4.5 billion dollars from drug dealing rare inherited disorders such as Gaucher and Fabry disease.

"Genzyme has demonstrated to all that the market for rare diseases can be quite profitable," said Gary Pisano, a professor at Harvard Business School and a specialist in biotechnology.

These drugs for rare diseases, so-called "orphan" can reach astronomical prices and yet are rarely rejected by insurance companies.Cerezyme, blockbuster treating Gaucher disease developed by Genzyme, is an annual treatment cost of over $ 200,000.

This is one of the drugs most expensive in the world and represented the last year a turnover of 1.2 billion dollars.

NEW PERSPECTIVES

They are new opportunities opening up for big pharmaceutical companies that are themselves, most often, little to offer in terms of experimental medicines.

"The era of 'blockbuster' seems gone," says Kevin Gorman (Putnam Associates). "In rare diseases needs to look far the greatest."

Gaucher disease and Fabry disease are characterized by an enzyme deficiency that can cause irreparable damage or even lethal to the organs.Treating such diseases is not accessible to all laboratories and even the big pharmaceutical companies are not equipped to start from scratch in this field.

Design in this field of rare diseases, clinical trials, control of complex manufacturing processes and finally market drugs in highly targeted markets, this requires a special skill mastery that Genzyme to perfection.

Yet, one case of infection occurred at the site last year Genzyme Allston Landing in Boston, led to a shortage of two key drugs and led to a sharp drop in results and a diving action.

Sanofi hopes to capitalize on woes Genzyme to buy cheap.It offers 69 dollars per share, according to sources familiar with the matter, much less than the $ 80 where work is changing before disorders occur manufacturing end of 2008.

According to sources, it is unlikely that Genzyme accepts less than 80 dollars per share. This can be explained by the fact that Genzyme is an asset as rare as the diseases it treats.

It is not likely to be subject to generic competition soon.It has also more than 20 years of experience in the relationship with patient groups in the organization of clinical trials and reimbursement management and regulatory issues.

NOT EASY TO COPY

"The reasons why large groups are eyeing this segment reduced threat of generic products, products that can be expanded to other areas and prices," said Dominic Valder, an analyst at Evolution Securities.

Traditionally, the big pharmaceutical companies focus on drugs prescribed by GPs in a large population of patients with chronic conditions like diabetes, depression, ulcers or cholesterol is too high.

These medicines are made from molecules that can easily replicate génériquiers.

The biotech drugs are on the contrary from protein complex. They are prescribed by specialists for patients in small numbers. They are not easy to copy.

Some heavyweights pharmacy try their luck but so timidly.For Patrick Vallance, head of research at Glaxo, the strategy aims to improve the returns to research and development focusing on areas where the probability of success are greatest.

Glaxo has taken a stake in the Japanese and JCR Pharmaceuticals has entered into an alliance with privately held Prosensa, leading to the launch of a Phase III clinical trial in the second half and bearing on Duchenne muscular dystrophy.

Pfizer has acquired worldwide rights to an experimental treatment for Gaucher disease developed by Protalix BioTherapeutics, which if approved, would compete with Genzyme's Cerezyme.

Carphone Warehouse, the first European distributor of mobile phones, publishes quarterly results above its forecast, thanks to smartphone demand, pushing up the stock price of more than 5%.

The British group showed some caution about the economic climate but said he was confident, however, achieve its goal for the year in April.

Of the thirteen weeks to July 3, the first fiscal quarter, sales in stores open at least a year rose 3.7% at constant exchange rates in the European market.

This increase is greater than analysts' forecasts that anticipated growth of 2%, according to a survey conducted by the company.

Carphone has also said that the three new stores opened since April in Britain under the name Best Buy have been successful had a "very positive", without giving figures.

Asked by Reuters about the economic outlook, the group general manager Roger Taylor said: "I am not a prophet of doom. But I do not presume to rapid growth, either."

The title gained 5.09% to 227 pence at 10h00 GMT, the FTSE 100 yielded 0.19%.

DuPont publishes a quarterly profit nearly tripled thanks to a double digit growth in sales in its five main business segments.

The number three of the chemistry in the United States has achieved during April-June net profit of 1.17 billion (900 million euros), or $ 1.26 per share, against 417 million (41 cents / share) on the corresponding period last year.

Excluding items, earnings were $ 1.17 per share.

Financial analysts had expected earnings of 93 cents per share according to Thomson Reuters I / B / E / S.It was not clear immediately that this consensus is comparable to published results.

The quarterly revenue rose 25.6% to $ 8.62 billion against 8.27 billion expected by the market.

DuPont revised upwards its forecast range for the full year, saying it now expects earnings per share (EPS) of 2.90 to 3.05 dollars excluding special items, against 2.50 to 2.70 far.

The market consensus gives an annual EPS of 2.64 dollars.

The action DuPont, one of the 30 stocks in the Dow Jones gained 2.1% in pre-market transactions, to 39.80 dollars.

Electrolux reported an operating profit below expectations for the second quarter and reaffirmed its forecast of a rise in demand this year in its main markets.

Operating income was 1.5 billion kronor (157 million) excluding exceptional items, against one billion kroner in the second quarter of 2009.The 17 banks and brokerages surveyed by Reuters had expected a net profit of 1.6 billion kronor for the period Apr-Jun 2010.

At 7:36 GMT, yielded 5.0% to 158.70 kronor on the Stockholm Stock Exchange.

"The demand for appliances on the group's main markets should be growing during 2010," the Swedish group in a statement.

The second largest manufacturer of household appliances has been forced to sharply reduce its costs to cope with the slowdown in consumption last year but said its main markets had continued to recover in the second quarter.

Electrolux said the North American market had risen for the third consecutive quarter after 13 quarters of contraction.

"At the industry level, the supply of aircraft destined for the United States in the second quarter would have increased approximately 10%," the group said.

"The entire European market has stabilized during the quarter, with major markets such as Germany, France and Sweden showing positive trends," he added, while noting that southern markets Europe had suffered a sharp slowdown over the period.

'The demand in eastern Europe has increased somewhat, further stated Electrolux.

The U.S. stocks have ended without major trend Wednesday as investors wondering about the tone set by the Fed in the minutes of the last meeting of its Monetary Policy Committee.

The Federal Reserve said that its members should be prepared to adopt new measures to support the economy if the environment deteriorates.

See Fed talk about slowing down and hear that she may have to provide more support and cash undoubtedly shaken the markets, "said Bruce Zaro, chief investment strategist for Delta Global Advisors.

The Dow Jones, which includes the thirty most important values of American industry, was up 0.04% to 10.366.72 points, the S & P 500 index fund managers, dropped 0.02% to 1095.17 points.

The Nasdaq's side showed signs of resistance, clinching 0.35% to 2224.84 points, thanks to technology, supported by better than expected results released Tuesday by Intel. The title of the Informatics Group closed up 1.67% to 21.36 dollars.

Investors have also learned the consequences of the publication of statistics showing that business inventories had risen less sharply than expected in the United States in May while sales fell for the first time since March 2009.

The S & P showing variations of values related to consumption has dropped 0.54%.Abercrombie & Fitch has lost 0.83% to 35.93 dollars while JCPenney yielded 0.86% to 22.99 dollars.

The bank has also been the subject of intense clearances pending the results of resistance testing is suffered by 91 European banks.

The KBW index of sectoral sector fell 1.61%.

A reversal of the trend, GlaxoSmithKline closed up 1.76% to 36.35 dollars after the positive vote from the Food and Drug Administration on a diabetic, developed by the laboratory.

Business start-ups have increased by 1.0% in June to sign up 43.2% over 12 months, according to figures released Tuesday by the INSEE.

In June, the INSEE counted 24,182 new businesses in seasonally adjusted data (+18.4%), a figure which rises to 50,508 by counting the self-entrepreneurs, the figures for the latter being in the raw data.

The lower number of new self-entrepreneurs in June was offset by higher self-creations out contractors, "said INSEE in its statement.

In May, the number of new non-auto business had increased by 2.7% to 20,426.Including these, INSEE had counted 50,021 designs.

Year over year the last three months, the cumulative number of creations in the second quarter 2010 was up slightly compared to second quarter 2009 (+2.1%). The sectors that contribute most to this increase were the construction and industry, noted INSEE.

In the first six months of the year there are 200,313 requests for creations under the self-contractor.

The statute, which simplifies administrative procedures and is fiscally advantageous, has attracted 320,000 people its first year and the Secretary of State for Trade Herve Novelli in hopes as many this year.

The release can be found at www.insee.fr

The CEO of BP's Tony Hayward met with officials of the Abu Dhabi Investment Authority (Adia), one of the largest SWFs in the world, said an official source of United Arab Emirates (UAE).

A UAE source told Reuters on Tuesday that BP had approached sovereign wealth funds to find a strategic partner to preserve it from any takeover attempt as it is mobilized by an oil spill that has caused the Gulf of Mexico.

Tony Hayward has made various "options" at this meeting, added the official source, without being more explicit.

Adia was not immediately available for comment.

A Saudi financial daily reported Wednesday that Saudi investors wishing to enter the capital of BP at 10% to 15%.

A delegation of these investors will travel to London to begin a dialogue with BP, said al-Eqtisadiyah, the main financial newspaper in the kingdom, without citing sources.

Action BP has lost more than half its value since the oil spill that began last April.

The British oil giant said it hoped to raise 10 billion this year to finance a fund for cleaning $ 20 billion that had opened under pressure from Washington.

Action BP earns 4.17% to 360 pence in morning.

Bourbon has unveiled a new plan for the period 2011-2015 which includes the sale of its fleet of 16 bulk carriers and other non-core assets for a total of 500 million Euros.

The specialist maritime services to the offshore oil announced in a press release that it has signed an agreement to sell its Bulk with the American Genco Shipping & Trading Ltd for 545 million dollars (440 million euros).

As part of its strategic plan, Bourbon also wishes to invest two billion dollars (1.62 billion euros) in the construction of 80 supply vessels and 64 vessels transporting personnel to operate in 2015 a fleet 600 vessels dedicated logistics services in the continental offshore and deep offshore.

The offshore fleet amounted to 357 ships by end of 2009 and 99 are now in command in the context of its previous strategic plan.

"The bulk current activity will continue to a lesser extent and without the contribution of a fleet that is owned," said the CEO of Bourbon, Jacques de Chateauvieux, during a conference call."This is not disturbed our ability to meet the expectations of our customers."

Jacques de Chateauvieux has also indicated that the sugar activities of Bourbon in Vietnam, among other things, would be sold in addition to bulk carriers.

Apart from sales, financing the new investment program will be provided by changing the payment terms of vessels during construction, 75% of the price now being paid on delivery, as well as a 12-year loan of 400 million dollars granted by the China Exim Bank.

CASH FLOWS FROM POSITIVE in 2013

"The combined effect of generating cash flow from operations, disposal of assets in 2010 and the new payment policy should allow vessels a ratio of debt to equity of less than 0.5 and a ratio net debt / EBITDA of less than 2 by 2015.Bourbon and generate positive cash flow from 2013 onwards, "added the company.

Bourbon also said that its dividend policy would be to distribute approximately 40% of its consolidated net income.

After an average growth of 28% of the activity of its offshore division between 2002 and 2009, the new plan Bourbon displays a target of 17% average annual growth between 2011 and 2015.

The company is also concentrating on increasing the availability rate of the fleet with a goal of 95% against 92% today, and a decline in the index of its operational costs by 4% rate constant 2015.

Bourbon is also a ratio for 2015 gross operating profit (EBITDA) on revenues of 45% for offshore and an EBITDA ratio on capital employed of 20%.

It plans to recruit 5,000 people who join its 7,000 employees.

General Motors expects to publish in July a notice specifying the terms of an IPO that could reach 15 to $ 20 billion, said a source familiar with the matter.

In addition, GM's talks with JPMorgan Chase and Wells Fargo in a deal allowing the public to have easier access to car loans from dealers, said two people familiar with the discussions.

The managing director of GM Ed Whitacre and other executives have said their preference for an IPO this year.Bankers expect an IPO from 10 to 20 billion dollars per sale of a portion of the state participation is 60.8%.

15-20 billion, the IPO would be GM's most prominent feature in the U.S. since the $ 19.7 billion from Visa in March 2008, according to data from Thomson Reuters.

This is also one of the largest IPOs ever held in the United States.

The Treasury has made 50 billion dollars in aid to GM in 2009, including 43 billion in cash and nearly seven billion of direct loans.

The automaker has repaid the loans in April.

GM was not immediately available.